Epigral Limited

rs,

oor- 25, P J Tower, Dalal Street, Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation for Audited Financial Results – Q4 & FY2025 Ref.: Regulation 30 of the

76%

, however realization of Hydrogen Peroxide dropped o Captive consumption of Chlorine increased to 76% Q4FY25 Financial Highlights: o YoY Revenue grew by 20% to ₹ 631 Crore, on account volume growth

20%

ive consumption of Chlorine increased to 76% Q4FY25 Financial Highlights: o YoY Revenue grew by 20% to ₹ 631 Crore, on account volume growth from Derivative products o Revenue contribution from Der

₹ 631 Crore

sumption of Chlorine increased to 76% Q4FY25 Financial Highlights: o YoY Revenue grew by 20% to ₹ 631 Crore, on account volume growth from Derivative products o Revenue contribution from Derivatives & Spec

52%

rom Derivative products o Revenue contribution from Derivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITD

48%

oducts o Revenue contribution from Derivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at

12%

rom Derivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87

₹ 173 Crore

ivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87 Crore. PAT marg

₹ 155 Crore

ialty business increased to 52% in Q4FY25 vs 48% in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87 Crore. PAT margin stood at 14%

28%

in Q4FY24 o EBITDA grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87 Crore. PAT margin stood at 14% o ROCE grew to 25% as on 31st March 20

13%

grew by 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87 Crore. PAT margin stood at 14% o ROCE grew to 25% as on 31st March 2025 vs 18% as on 31st

₹ 87 Crore

y 12% to ₹ 173 Crore vs ₹ 155 Crore in Q4FY24 and EBITDA margin stood at 28% o PAT rose by 13% to ₹ 87 Crore. PAT margin stood at 14% o ROCE grew to 25% as on 31st March 2025 vs 18% as on 31st March 2024 du

“Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565”

Founded

1

Employees

1

Certified

1

Manufacturing facility

1

Integration

1

New Value Chains

1

Certified

Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565

Manufacturing facility

Fully-integrated & automated complex FY21 FY22 FY23 FY24 FY25 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) incorporated Commissioned 1st Plant Increased capacity to Commissioned • Caustic Potash – • Caustic Soda – 167 21 KTPA • Caustic Soda – 119 KTPA KTPA • CPP – 40 MW • CPP – 60 MW Converted all Membrane to Zero Gap Commissioned • Chloromethanes – 50 KTPA Announced Capex • Epichlorohydrin – 50 KTPA FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Commissioned • Hydrogen Peroxide – 60 KTPA Increased capacity to • Caustic Soda – 294 KTPA • CPP 96 MW Awarded “Responsible Care” Certificate Listed as an independent entity on 18th August 2021 Announced Capex • Chlorotoluene & Value Chain • Setting up R&D Centre Commissioned • Epichlorohydrin – 50 KTPA • CPVC Resin – 30 KTPA Renamed compa

Integration

o Scale up capacities in existing products o New value added products in existing value chains o Improved market position Opportunities in high growth sectors: o Explore opportunities in various sectors o Increase presence & improve market share o Entering into products which are fully imported

New Value Chains

o Expand chemistry expertise to enter new value chains (specialty chemicals) o Addition of new reaction capabilities Achieving economies of scale: o Optimising existing complex o Achieving efficiency operations to become a low cost producer Historical numbers Financial Performance – P&L Revenue (₹ Crore) EBITDA (₹ Crore and %) PAT (₹ Crore and %) 2,565 32% 33% 2,196 1,936 31% 689 25% 28% 711 1,555 831 509 481 261 16% 16% 12% 10% 353 253 196 14% 357 101 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 Margin -% Balance Sheet Ratios ROCE (%)# 32% 29% 25% ROE (%) 39% 36% Net Debt/EBITDA (x) 16% 17% 16% 17% 23% 2.1 1.9 2.0 1.3 0.7 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 #Capital employed in ROCE includes Capital Work in Progress Historic Income Statement Particulars (₹ Cr) FY2021 Total Revenue Gross Profit Gross Margin (%) EBITDA EBITDA Margin (%) Depreciation Finance Co